Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models

Frontiers in Pharmacology

Volumn 6, Issue MAY, 2015, Pages

  Lindsey Davis, S ^a,b   Robertson, Kelli M ^a   Pitts, Todd M ^a,b   Tentler, John J ^a,b   Bradshaw Pierce, Erica L ^a,b,c   Klauck, Peter J ^a   Bagby, Stacey M ^a   Hyatt, Stephanie L ^a   Selby, Heather M ^a   Spreafico, Anna ^a   Ecsedy, Jeffrey A ^d   Arcaroli, John J ^a,b   Messersmith, Wells A ^a,b   Tan, Aik Choon ^a,b   Gail Eckhardt, S ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b University of Colorado Cancer Center   (United States)

^c Takeda California   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Alisertib; Aurora A kinase; Colorectal cancer; Human tumor xenografts; KRAS mutation; MEK; PIK3CA; Trametinib

Indexed keywords

3 (2,3 DIHYDROXYPROPYL) 6 FLUORO 5 (2 FLUORO 4 IODOANILINO) 8 METHYLPYRIDO[2,3 D]PYRIMIDINE 4,7 DIONE; ALISERTIB; CASPASE 3; CASPASE 7; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN P53; TRAMETINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER SIZE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TREATMENT DURATION; TUMOR XENOGRAFT;

EID: 84930620876     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00120     Document Type: Article

References (42)

1. Amado, R.G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D.J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S.D., and Chang, D.D. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626-1634.
2. Andrysik, Z., Kim, J., Tan, A.C., and Espinosa, J.M. (2013). A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation. Cell Rep 3, 1346-1354.
3. Bennouna, J., Lang, I., Valladares-Ayerbes, M., Boer, K., Adenis, A., Escudero, P., Kim, T.Y., Pover, G.M., Morris, C.D., and Douillard, J.Y. (2011). A Phase II, open613 label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 29, 1021-1028.
4. Bradshaw-Pierce, E.L., Pitts, T.M., Kulikowski, G., Selby, H., Merz, A.L., Gustafson, D.L., Serkova, N.J., Eckhardt, S.G., and Weekes, C.D. (2013). Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One 8, e58089.
5. Caputo, E., Miceli, R., Motti, M., Tate, R., Fratangelo, F., Botti, G., Mozzillo, N., Carriero, M., Cavalcanti, E., Palmieri, G., Ciliberto, G., Pirozzi, G., and Ascierto, P. (2014). AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J Transl Med 12, 216.
6. Cervantes, A., Elez, E., Roda, D., Ecsedy, J., Macarulla, T., Venkatakrishnan, K., Rosello, S., Andreu, J., Jung, J., Sanchis-Garcia, J.M., Piera, A., Blasco, I., Manos, L., Perez-Fidalgo, J.A., Fingert, H., Baselga, J., and Tabernero, J. (2012). Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18, 4764-4774.
7. Chou, T.C., and Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55.
8. Collins S, B.D., Zarycki, Et Al (Year). "A rationale for combining the targed investigational agents TAK-733, a MEK 1/2 inhibitor, with alisertib (MLN8237), an Aurora A kinase inhibitor, in cancer", in: American Academy of Clinical Research Annual Meeting: American Academy of Clinical Research), 3738.
9. Crosio, C., Fimia, G.M., Loury, R., Kimura, M., Okano, Y., Zhou, H., Sen, S., Allis, C.D., and Sassone-Corsi, P. (2002). Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 22, 874-885.
10. De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K.T., Kotoula, V., Papamichael, D., Laurent-Puig, P., Penault-Llorca, F., Rougier, P., Vincenzi, B., Santini, D., Tonini, G., Cappuzzo, F., Frattini, M., Molinari, F., Saletti, P., De Dosso, S., Martini, M., Bardelli, A., Siena, S., Sartore-Bianchi, A., Tabernero, J., Macarulla, T., Di Fiore, F., Gangloff, A.O., Ciardiello, F., Pfeiffer, P., Qvortrup, C., Hansen, T.P., Van Cutsem, E., Piessevaux, H., Lambrechts, D., Delorenzi, M., and Tejpar, S. (2010). Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11, 753-762.
11. Dees, E.C., Cohen, R.B., Von Mehren, M., Stinchcombe, T.E., Liu, H., Venkatakrishnan, K., Manfredi, M., Fingert, H., Burris, H.A., 3rd, and Infante, J.R. (2012). Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18, 4775-4784.
12. Den Hollander, J., Rimpi, S., Doherty, J.R., Rudelius, M., Buck, A., Hoellein, A., Kremer, M., Graf, N., Scheerer, M., Hall, M.A., Goga, A., Von Bubnoff, N., Duyster, J., Peschel, C., Cleveland, J.L., Nilsson, J.A., and Keller, U. (2010). Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116, 1498-1505.
13. Diamond, J.R., Bastos, B.R., Hansen, R.J., Gustafson, D.L., Eckhardt, S.G., Kwak, E.L., Pandya, S.S., Fletcher, G.C., Pitts, T.M., Kulikowski, G.N., Morrow, M., Arnott, J., Bray, M.R., Sidor, C., Messersmith, W., and Shapiro, G.I. (2011). Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 17, 849-860.
14. Douillard, J.Y., Oliner, K.S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., Rivera, F., Kocakova, I., Ruff, P., Blasinska-Morawiec, M., Smakal, M., Canon, J.L., Rother, M., Williams, R., Rong, A., Wiezorek, J., Sidhu, R., and Patterson, S.D. (2013). Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369, 1023-1034.
15. Duncan, J.S., Whittle, M.C., Nakamura, K., Abell, A.N., Midland, A.A., Zawistowski, J.S., Johnson, N.L., Granger, D.A., Jordan, N.V., Darr, D.B., Usary, J., Kuan, P.F., Smalley, D.M., Major, B., He, X., Hoadley, K.A., Zhou, B., Sharpless, N.E., Perou, C.M., Kim, W.Y., Gomez, S.M., Chen, X., Jin, J., Frye, S.V., Earp, H.S., Graves, L.M., and Johnson, G.L. (2012). Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321.
16. Falchook, G., Kurzrock, R., Gouw, L., Hong, D., Mcgregor, K.A., Zhou, X., Shi, H., Fingert, H., and Sharma, S. (2014). Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs 32, 1181-1187.
17. Flaherty, K.T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., Dummer, R., Trefzer, U., Larkin, J.M., Utikal, J., Dreno, B., Nyakas, M., Middleton, M.R., Becker, J.C., Casey, M., Sherman, L.J., Wu, F.S., Ouellet, D., Martin, A.M., Patel, K., Schadendorf, D., and Group, M.S. (2012). Improved survival with MEK inhibition in BRAF mutated melanoma. N Engl J Med 367, 107-114.
18. Flanigan, S.A., Pitts, T.M., Newton, T.P., Kulikowski, G.N., Tan, A.C., Mcmanus, M.C., Spreafico, A., Kachaeva, M.I., Selby, H.M., Tentler, J.J., Eckhardt, S.G., and Leong, S. (2013). Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res 19, 6219-6229.
19. Gartel, A.L., and Tyner, A.L. (2002). The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1, 639-649.
20. Heinemann, V., Von Weikersthal, L.F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.E., Heintges, T., Lerchenmuller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Hielscher, J., Scholz, M., Muller, S., Link, H., Niederle, N., Rost, A., Hoffkes, H.G., Moehler, M., Lindig, R.U., Modest, D.P., Rossius, L., Kirchner, T., Jung, A., and Stintzing, S. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol.
21. Hilton, J.F., and Shapiro, G.I. (2014). Aurora kinase inhibition as an anticancer strategy. J Clin Oncol 32, 57-59.
22. Hirota, T., Kunitoku, N., Sasayama, T., Marumoto, T., Zhang, D., Nitta, M., Hatakeyama, K., and Saya, H. (2003). Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114, 585-598.
23. Hochster, H.S., Uboha, N., Messersmith, W., Gold, P.J., Bh, O.N., Cohen, D., Denlinger, C., Cohen, S., Leichman, C.G., and Leichman, L. (2015). Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol 75, 17-23.
24. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O'callaghan, C.J., Tu, D., Tebbutt, N.C., Simes, R.J., Chalchal, H., Shapiro, J.D., Robitaille, S., Price, T.J., Shepherd, L., Au, H.J., Langer, C., Moore, M.J., and Zalcberg, J.R. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359, 1757-1765.
25. Katayama, H., Sasai, K., Kawai, H., Yuan, Z.M., Bondaruk, J., Suzuki, F., Fujii, S., Arlinghaus, R.B., Czerniak, B.A., and Sen, S. (2004). Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36, 55-62.
26. Koch, G., Walz, A., Lahu, G., and Schropp, J. (2009). Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 36, 179-197.
27. Kollareddy, M., Zheleva, D., Dzubak, P., Brahmkshatriya, P.S., Lepsik, M., and Hajduch, M. (2012). Aurora kinase inhibitors: Progress towards the clinic. Investigational New Drugs 30, 2411-2432.
28. Kopetz S, D.J., Chan E, Hecht Jr, O'dwyer P, Lee Rj, et al. (Year). "PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors", in: ASCO Annual Meeting: Journal of Clinical Oncology), Abstr 3534.
29. Lens, S.M., Voest, E.E., and Medema, R.H. (2010). Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer 10, 825-841.
30. Lindqvist, A., Rodriguez-Bravo, V., and Medema, R.H. (2009). The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol 185, 193-202.
31. Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., De Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.J., Sileni, V.C., Lebbe, C., Mandala, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J.B., Hansson, J., Utikal, J., Ferraresi, V., Kovalenko, N., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Demarini, D.J., Irani, J.G., Casey, M., Ouellet, D., Martin, A.M., Le, N., Patel, K., and Flaherty, K. (2014). Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med.
32. Lu, L., Han, H., Tian, Y., Li, W., Zhang, J., Feng, M., and Li, Y. (2014). Aurora kinase A mediates c-Myc's oncogenic effects in hepatocellular carcinoma. Mol Carcinog.
33. Manfredi, M.G., Ecsedy, J.A., Chakravarty, A., Silverman, L., Zhang, M., Hoar, K.M., Stroud, S.G., Chen, W., Shinde, V., Huck, J.J., Wysong, D.R., Janowick, D.A., Hyer, M.L., Leroy, P.J., Gershman, R.E., Silva, M.D., Germanos, M.S., Bolen, J.B., Claiborne, C.F., and Sells, T.B. (2011). Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 17, 7614-7624.
34. Marxer, M., Ma, H.T., Man, W.Y., and Poon, R.Y. (2014). p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases. Oncogene 33, 3550-3560.
35. Melino, G., De Laurenzi, V., and Vousden, K.H. (2002). p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2, 605-615.
36. Moll, U.M., Wolff, S., Speidel, D., and Deppert, W. (2005). Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 17, 631-636.
37. Pages, G., Lenormand, P., L'allemain, G., Chambard, J.C., Meloche, S., and Pouyssegur, J. (1993). Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 90, 8319-8323.
38. Perez De Castro, I., Aguirre-Portoles, C., Fernandez-Miranda, G., Canamero, M., Cowley, D.O., Van Dyke, T., and Malumbres, M. (2013). Requirements for Aurora-A in tissue regeneration and tumor development in adult mammals. Cancer Res 73, 6804-6815.
39. Spreafico, A., Tentler, J.J., Pitts, T.M., Tan, A.C., Gregory, M.A., Arcaroli, J.J., Klauck, P.J., Mcmanus, M.C., Hansen, R.J., Kim, J., Micel, L.N., Selby, H.M., Newton, T.P., Mcphillips, K.L., Gustafson, D.L., Degregori, J.V., Messersmith, W.A., Winn, R.A., and Eckhardt, S.G. (2013). Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer. Clin Cancer Res 19, 4149-4162.
40. Von Euw, E., Atefi, M., Attar, N., Chu, C., Zachariah, S., Burgess, B.L., Mok, S., Ng, C., Wong, D.J., Chmielowski, B., Lichter, D.I., Koya, R.C., Mccannel, T.A., Izmailova, E., and Ribas, A. (2012). Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer 11, 22.
41. Wei, F., Yan, J., and Tang, D. (2011). Extracellular signal-regulated kinases modulate DNA damage response-a contributing factor to using MEK inhibitors in cancer therapy. Curr Med Chem 18, 5476-5482.
42. Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J.H., Spano, J.P., Middleton, M.R., Calvo, E., Paz-Ares, L., Larkin, J., Pacey, S., Venturi, M., Kraeber-Bodere, F., Tessier, J.J., Eberhardt, W.E., Paques, M., Guarin, E., Meresse, V., and Soria, J.C. (2014). Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin Cancer Res 20, 4251-4261.